

1 **SUPPLEMENTAL MATERIAL**

2

3 **Table S1. Lymph node dissection other than sentinel lymph node.**

<b>Characteristic</b>	<b>Node negative cohort N=452</b>	<b>SLN-ITC cohort N=42</b>	<b>P<sup>†</sup></b>
Pelvic LND			0.99
No	379 (83.8)	35 (83.3)	
Yes	73 (16.2)	7 (16.7)	
Positive pelvic LND			-
No	452 (100.0)	42 (100.0)	
Yes	0	0	
Paraortic LND			0.30
No	449 (99.3)	41 (97.6)	
Yes	3 (0.7)	1 (2.4)	
Positive paraortic LND			-
No	452 (100.0)	42 (100.0)	
Yes	0	0	

4 **Abbreviations: ITC, isolated tumor cell; LND, lymphadenectomy; SLN, sentinel lymph node.**5 **<sup>†</sup>Fisher's exact test P value.**

6

7

8

9

10

11 **Table S2. Patients with recurrence** \*.

12

<b>Patient</b>	<b>SLN node status</b>	<b>Age at surgery (years)</b>	<b>FIGO grade</b>	<b>LVSI</b>	<b>MI (%)</b>	<b>Peritoneal cytology</b>	<b>Largest tumor diameter (mm)</b>	<b>Number of SLNs removed</b>	<b>LND pathology (# nodes removed: P, PA)</b>	<b>Recurrence</b>	<b>Time to first recurrence (months)</b>	<b>Treatment of first recurrence</b>	<b>Vital status</b>
1	Node Negative	73	1	No	0	Not sampled	28	7	No LND	Peritoneal	18.1	CT	Dead
2	ITC	83	1	No	38	Negative	43	3	No LND	Hematogenous	23.1	Unknown	Dead
3	Node Negative	64	1	No	17	Negative	60	3	No LND	Lymphatic (pelvic and paraaortic)	23.2	EBRT	Alive
4	Node Negative	84	1	No	0	Negative	1	3	Negative (17)	Other (vulvar)	32.3	Surgery	Alive
5	Node Negative	61	1	No	10	Positive	26	2	Negative (10)	Hematogenous and peritoneal	44.9	CT	Alive
6	Node Negative	57	1	No	47	Negative	55	5	No LND	Hematogenous and lymphatic (pelvic and paraaortic)	57.7	CT	Dead
7	Node Negative	62	1	Yes	37	Not sampled	34	5	No LND	Hematogenous	43.9	Letrozole	Alive
8	ITC	58	2	No	20	Negative	48	4	No LND	Lymphatic (pelvic)	11.7	None	Alive

9	ITC	58	2	No	10	Not sampled	45	3	Negative (15, 21)	Peritoneal and vaginal	6.0	CT	Alive
10	Node Negative	79	2	No	35	Negative	29	3	No LND	Hematogenous and vaginal	14.2	CT+EBRT+ pembrolizumab	Dead
11	Node Negative	65	2	No	0	Negative	72	3	No LND	Lymphatic (pelvic) and peritoneal	17.1	CT	Alive
12	Node Negative	57	2	No	27	Negative	11	2	No LND	Hematogenous	51.3	CT	Alive
13	Node Negative	61	2	No	45	Negative	36	4	No LND	Lymphatic (pelvic)	57.2	Surgery+CT+EBRT	Alive
14	Node Negative	79	2	No	8	Negative	18	4	No LND	Peritoneal and vaginal	57.3	None	Dead
15	ITC	60	2	Yes	44	Not sampled	/	2	No LND	Lymphatic (pelvic and groin)	4.3	CT+EBRT+VB	Alive
16	Node Negative	66	1	No	17	Negative	70	4	No LND	Vaginal	21.1	EBRT	Alive
17	Node Negative	61	1	No	12	Negative	62	4	No LND	Vaginal	25.5	Surgery	Alive
18	ITC	65	1	Yes	26	Negative	37	2	No LND	Vaginal	14.7	CT+EBRT+VB	Alive

19	Node Negative	48	2	No	48	Negative	78	2	No LND	Vaginal	7.8	Surgery+CT	Alive
20	Node Negative	59	2	No	0	Negative	35	2	No LND	Vaginal	30.6	EBRT+VB	Alive
21	Node Negative	58	2	Yes	23	Not sampled	41	3	No LND	Vaginal	26.1	EBRT+VB	Alive

13

14

15 **Abbreviations: BMI, body mass index; CT, chemotherapy; EBRT, external beam radiation therapy; FIGO, International Federation of**  
 16 **Gynecology and Obstetrics; LND, lymphadenectomy; LVSI, lymphovascular space invasion; MI, myometrial invasion; P, pelvic; PA,**  
 17 **paraaortic; SLN, sentinel lymph node; VB, vaginal brachytherapy; ITC, isolated tumor cells.**

18 **\*All patients listed were FIGO stage IA and had bilateral SLN removal.**

19

20 **Table S3. Distribution of non-vaginal recurrences among the overall low-risk population**  
 21 **(stage IA, endometrioid histology, grade 1 or 2) according to the main histopathological**  
 22 **features.**  
 23

SLN node status	Grade	LVSI	N	N of patients with non-vaginal recurrence (%)	Years to recurrence Median (range)
Node negative	1	No	342	5 (1.5)	2.7 (1.5-4.8)
Node negative	1	Yes	5	1 (20.0)	3.7 (-)
Node negative	2	No	103	5 (4.9)	4.3 (1.2-4.8)
Node negative	2	Yes	2	0 (0)	-
ITC	1	No	24	1 (4.2)	1.9 (-)
ITC	1	Yes	5	0 (0)	-
ITC	2	No	11	2 (18.2)	0.7 (0.5-1.0)
ITC	2	Yes	2	1 (50.0)	0.4 (-)

24  
 25 **Abbreviations: ITC, isolated tumor cell; LVSI, lymphovascular space invasion; SLN, sentinel**  
 26 **lymph node.**  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56

## Appendix

57

58

### 59 *Surgical management*

60

61 All patients underwent surgical staging for endometrial cancer (including hysterectomy, bilateral  
62 salpingo-oophorectomy, and SLN biopsy) at one of the participating centers. Sentinel lymph node  
63 mapping was performed following National Comprehensive Cancer Network (NCCN) SLN  
64 mapping guidelines (1). SLNs were ultrastaged using the Memorial Sloan-Kettering Cancer Center  
65 approach (2) or a modification of this protocol based on each institution's anatomic pathology  
66 protocols.

67

### 68 *Data collection*

69 Each participating center collected data regarding demographic, clinical, tumor, treatment, and  
70 outcome characteristics. Demographic, clinical, and pathology data were obtained by reviewing the  
71 electronic medical record and entered in a secure REDCap database, as previously described (3).  
72 Location of the recurrence was classified as: vaginal, peritoneal, hematogenous, lymphatic (pelvic,  
73 paraaortic, other distant lymphatic – inguinal, mediastinal, supraclavicular). Non-vaginal  
74 recurrence was defined as recurrence localized to the lymph nodes or peritoneum or was distant  
75 through hematogenous spread, with or without concomitant vaginal recurrence.

76

77

### 78 *Statistical methods*

79 Clinicopathologic characteristics and variables of lymph node dissection other than SLN were  
80 compared between two cohorts (SLN-ITC patients versus node-negative patients) utilizing chi-square  
81 or Fisher's exact tests for categorical variables and the two-sample t-test for continuous variables.  
82 The Kaplan-Meier method was used to estimate overall, recurrence-free, and non-vaginal recurrence-  
83 free survival by cohort, SLN-ITC and node-negative patients, restricting follow-up to the first 5 years  
84 after surgery. These were repeated excluding patients with lymphovascular space invasion. Time-to-  
85 event was calculated from the date of surgery to the date of death or last follow-up for overall survival

86 and from the date of surgery to the date of recurrence or last relevant clinical follow-up for recurrence-  
87 free survival.

88 Univariate and multivariable Cox proportional hazards regression models were fit to evaluate the  
89 association between clinicopathologic characteristics with death and recurrence (any and non-  
90 vaginal). Associations were summarized with a hazard ratio (HR) and 95% confidence interval (CI).  
91 All calculated P values were two-sided, and  $P < 0.05$  was considered statistically significant. Statistical  
92 analyses were performed using the SAS 9.4 (SAS Institute, Inc).

93

94

95 *References*

96

- 97 1. Koh W-J, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine  
98 neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. *Journal of the National*  
99 *Comprehensive Cancer Network*. 2018;16(2):170-99.
- 100 2. Kim CH, Soslow RA, Park KJ, Barber EL, Khoury-Collado F, Barlin JN, et al. Pathologic  
101 ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer  
102 staging. *Int J Gynecol Cancer*. 2013;23(5):964-70.
- 103 3. Ghoniem K, Larish AM, Dinoi G, Zhou XC, Alhilli M, Wallace S, et al. Oncologic outcomes  
104 of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An  
105 international multi-institutional study. *Gynecol Oncol*. 2021;162(3):590-8.

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128 **LIST OF IRB CENTERS**

129

- 130 • Hospital Clínic de Barcelona Ethics Committee, ES
- 131 • Ethikkommission der Medizinischen Universität Graz, AT
- 132 • Sunnybrook research ethics board, USA
- 133 • Comitato Etico Territoriale Lombardia 4, IT
- 134 • Comitê de Ética em Pesquisa - Fundacao Antonio Prudente, BR
- 135 • The University of Wisconsin Health Sciences IRB , USA
- 136 • Research Ethical Committee of La Paz University Hospital- IdiPAZ. Madrid, ES
- 137 • Comitato Etico Territoriale Lombardia 3 ATS Brianza , IT
- 138 • Comitato Etico Territoriale Lombardia 2, IT
- 139 • Comitato Etico Palermo 2 , IT
- 140 • Hartford HealthCare (HHC) Institutional Review Board (IRB), USA
- 141 • Cleveland Clinic Foundation - Florida Institutional Review Board, USA
- 142 • Meir Medical Center Helsinki Committee, IL
- 143 • Mater Human Research Ethics Committee (HREC), AU
- 144 • Comitato Etico Azienda Ospedaliero-Universitaria di Cagliari - Ex Comitato Etico
- 145 Indipendente della A.O.U. di Cagliari, IT
- 146 • Penn IRB, USA
- 147 • Research Ethics Committee (CEI UNAV), Universidad de Navarra, ES
- 148 • Comité de Revisión Institucional del Hospital Británico de Buenos Aires (CRIHB), ARG
- 149 • Comité de Ética de Investigación (CEI) del Hospital Puerta de Hierro Majadahonda, ES
- 150 • Ethics Committee, Curie Institute, FR
- 151 • Koç University Ethical Committees, TRKY
- 152 • Lahey Hospital & Medical Center's Institutional Review Board (IRB), USA
- 153 • BSD/UCMC Institutional Review Boards, USA
- 154